secwatch.observer — SEC 8-K summary
======================================

Issuer:     Axogen, Inc. (AXGN)
CIK:        0000805928
Form:       8-K
Filed at:   2024-09-06T23:59:59+00:00
Accession:  0000805928-24-000127
Event type: regulatory
Sentiment:  neutral
Materiality: 0.65
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Axogen completes BLA submission to FDA for Avance Nerve Graft; priority review requested
--------------------------------------------------------------------------------

- FDA submission for Avance Nerve Graft completed under rolling review process on Sept. 6, 2024.
- Company requested priority review; if granted, review timeline could be 6 months vs. standard 10 months.
- Avance previously received RMAT designation from FDA under 21st Century Cures Act.
- FDA expected to notify acceptance and confirm review timeline within approximately 60 days.
- Company on track for FDA approvability determination between April and September 2025.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/805928/000080592824000127/0000805928-24-000127-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/805928/000080592824000127/axgn-20240906.htm
  HTML page:      https://secwatch.observer/filing/0000805928-24-000127

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer